Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism - PubMed (original) (raw)
. 2002 Apr 9;41(14):4595-602.
doi: 10.1021/bi0121353.
Affiliations
- PMID: 11926821
- DOI: 10.1021/bi0121353
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism
Michael J Volles et al. Biochemistry. 2002.
Abstract
Two mutations in the protein alpha-synuclein (A30P and A53T) are linked to an autosomal dominant form of Parkinson's disease. Both mutations accelerate the formation of prefibrillar oligomers (protofibrils) in vitro, but the mechanism by which they promote toxicity is unknown. Protofibrils of wild-type alpha-synuclein bind and permeabilize acidic phospholipid vesicles. This study examines the relative membrane permeabilizing activities of the wild type, mutant, and mouse variants of protofibrillar alpha-synuclein and the mechanism of membrane permeabilization. Protofibrillar A30P, A53T, and mouse variants were each found to have greater permeabilizing activities per mole than the wild-type protein. The leakage of vesicular contents induced by protofibrillar alpha-synuclein exhibits a strong preference for low-molecular mass molecules, suggesting a pore-like mechanism for permeabilization. Under conditions in which the vesicular membrane is less stable (lack of calcium as a phospholipid counterion), protofibril permeabilization is less size-selective and monomeric alpha-synuclein can permeabilize via a detergent-like mechanism. We conclude that the pathogenesis of Parkinson's disease may involve membrane permeabilization by protofibrillar alpha-synuclein, the extent of which will be strongly dependent on the in vivo conditions.
Similar articles
- Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. Lashuel HA, et al. J Mol Biol. 2002 Oct 4;322(5):1089-102. doi: 10.1016/s0022-2836(02)00735-0. J Mol Biol. 2002. PMID: 12367530 - Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr. Volles MJ, et al. Biochemistry. 2001 Jul 3;40(26):7812-9. doi: 10.1021/bi0102398. Biochemistry. 2001. PMID: 11425308 - Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ, Lansbury PT Jr. Volles MJ, et al. Biochemistry. 2003 Jul 8;42(26):7871-8. doi: 10.1021/bi030086j. Biochemistry. 2003. PMID: 12834338 Review. - Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. Rochet JC, et al. J Mol Neurosci. 2004;23(1-2):23-34. doi: 10.1385/jmn:23:1-2:023. J Mol Neurosci. 2004. PMID: 15126689 Review.
Cited by
- Structural intermediates during α-synuclein fibrillogenesis on phospholipid vesicles.
Comellas G, Lemkau LR, Zhou DH, George JM, Rienstra CM. Comellas G, et al. J Am Chem Soc. 2012 Mar 21;134(11):5090-9. doi: 10.1021/ja209019s. Epub 2012 Mar 12. J Am Chem Soc. 2012. PMID: 22352310 Free PMC article. - Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis.
Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O'Connor C, Wiethoff CM, Campbell EM. Freeman D, et al. PLoS One. 2013 Apr 25;8(4):e62143. doi: 10.1371/journal.pone.0062143. Print 2013. PLoS One. 2013. PMID: 23634225 Free PMC article. - Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Fields CR, et al. Front Mol Neurosci. 2019 Dec 5;12:299. doi: 10.3389/fnmol.2019.00299. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31866823 Free PMC article. Review. - Peroxidative aggregation of alpha-synuclein requires tyrosines.
Olteanu A, Pielak GJ. Olteanu A, et al. Protein Sci. 2004 Nov;13(11):2852-6. doi: 10.1110/ps.04947204. Epub 2004 Sep 30. Protein Sci. 2004. PMID: 15459341 Free PMC article. - The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration.
Yamamoto A, Simonsen A. Yamamoto A, et al. Neurobiol Dis. 2011 Jul;43(1):17-28. doi: 10.1016/j.nbd.2010.08.015. Epub 2010 Aug 20. Neurobiol Dis. 2011. PMID: 20732422 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous